On September 6, 2022 Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, reported that the Company will participate in the following upcoming investor conferences taking place in New York (Press release, Arbutus Biopharma, SEP 6, 2022, View Source [SID1234619014]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 24th Annual Global Investment Conference (September 12-14, 2022)

Company Presentation: Tuesday, September 13th at 12:30 pm ET
Presenter: William Collier, President & Chief Executive Officer
Baird’s 2022 Global Healthcare Conference (September 13-14, 2022)

Fireside Chat: Wednesday, September 14th at 10:15 am ET
Presenters: William Collier, President & Chief Executive Officer; Dr. Gaston Picchio, Chief Development Officer; Michael McElhaugh, Chief Business Officer; and David Hastings, Chief Financial Officer
Live webcasts of the presentation and fireside chat can be accessed through the Investors section of Arbutus’ website at www.arbutusbio.com. An archived replay of the webcast will be available on the Arbutus website after the event.